Galactooligosaccharides Suppress the Development of Biofilm in the Presence of Blood Polymorphonuclear Cells of Non-Small Cell Lung Cancer (NSCLC) Patients: A Pilot Study.

Masoumeh Nomani, Babak Salimi, Mohammad Varahram, Hamidreza Jamaati, Esmaeil Mortaz

Abstract read

In one paragraph

Article in Tanaffos, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Masoumeh NomaniClinical Tuberculosis and Epidemiology Research Center, National Research Institute of Tuberculosis and Lung Diseases(NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Babak SalimiClinical Tuberculosis and Epidemiology Research Center, National Research Institute of Tuberculosis and Lung Diseases(NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Mohammad VarahramMycobacteriology Research Center, NRITLD, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Hamidreza JamaatiChronic Respiratory Diseases Research Center, NRITLD, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Esmaeil MortazClinical Tuberculosis and Epidemiology Research Center, National Research Institute of Tuberculosis and Lung Diseases(NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Bacterial biofilms pose a significant healthcare challenge due to their robust resistance to antibiotics and their involvement in various diseases, including cancer and infectious conditions. Biofilms hinder the antimicrobial activity of polymorphonuclear leukocytes (PMNs) by restricting their penetration through the extracellular matrix. With the rise of antimicrobial resistance, non-antibiotic strategies are gaining attention. Galacto-oligosaccharides (GOS) have been investigated for their potential to inhibit bacterial growth. This study investigates the impact of GOS on the biofilm development of GFP-labelled Results: GOS itself, with bacteria at high concentrations (10%, 15%, and 20%), suppressed biofilm formation. PMNs of NSCLC patients show higher biofilm formation than in the absence of PMNs. Conclusion: Based on our findings, PMNs in NSCLC patients may disrupt the natural balance of bacteria in the lungs, potentially leading to an overgrowth of biofilm-forming bacteria. GOS are known to influence immune function and may improve the ability of PMNs to fight infections. Consequently, it is proposed that GOS could enhance the ability of PMNs to phagocytose bacterial biofilms and counteract the negative effects of cancerous PMNs on biofilm formation. However, further research is needed to confirm whether GOS can effectively manage bacterial biofilms in lung cancer patients.

Indexed as

BiofilmGalacto-oligosaccharides (GOS)NSCLC patientsPhagocytosisPolymorphonuclear leukocytes (PMNs)Pseudomonas aeruginosaStaphylococcus aureus

Identifiers

PMID42890051

PMCPMC13672036

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.